

Cytotoxicity of phenylpropanoid esters from the stems of *Hibiscus taiwanensis*

Pei-Lin Wu,* Ta-Hsien Chuang, Cai-Xia He and Tian-Shung Wu*

Department of Chemistry, National Cheng Kung University, Tainan 701, Taiwan, ROC

Received 9 December 2003; revised 16 February 2004; accepted 17 February 2004

Abstract—The separation of an extract prepared from the stems of the previously uninvestigated *Hibiscus taiwanensis* led to the isolation of three new phenylpropanoid esters, (7*S*,8*S*)-demethylcarolignan E (**1**), hibiscuwanin A (**2**), hibiscuwanin B (**3**), in addition to eight known ones. The structures of these compounds were elucidated by spectroscopic and chemical transformation studies. In cytotoxicity evaluation of the isolates, 9,9'-*O*-feruloyl-(–)-secoisolaricinresinol (**8**) showed strong cytotoxic activity against human lung carcinoma and breast carcinoma cell lines in an in vitro cytotoxicity assay with EC₅₀ values of 1.8 and 3.9 µg/mL, respectively.

© 2004 Elsevier Ltd. All rights reserved.

1. Introduction

Hibiscus taiwanensis Hu, indigenous to Taiwan, is a moderate shrub and widely distributed throughout Taiwan.¹ This species belongs to the Malvaceae family comprised of 75 genera of herbaceous plants and shrubs distributed throughout tropical and temperate region. Species from the genus *Hibiscus* have been used in several applications, such as antidote to poisoning with chemicals and venomous mushrooms in traditional medicine and as a source of fibre to pulp and paper industries. A literature review indicated that this genus is a source of lignanamides, naphthalenes, polyphenol compounds, carotenoids, anthocyanins, sterols and long chain fatty esters. To our knowledge, there are no previous reports of chemical and biological studies on *H. taiwanensis*. In the course of our programme to study cytotoxic constituents from plant resources, *H. taiwanensis* was chosen for detailed chemical investigation due to the promising cytotoxic activity of the crude methanolic extract against gastric and nasopharyngeal carcinoma cell lines revealed in the preliminary screen.² The water soluble portion of the methanolic extract from the stems of *H. taiwanensis* was defatted with hexane and then partitioned with CHCl₃ and EtOAc, successively.

Three new phenylpropanoid esters, (7*S*,8*S*)-demethylcarolignan E (**1**), hibiscuwanin A (**2**), hibiscuwanin B (**3**) and eight known phenylpropanoids, *threo*-carolignan E (**4**),³ *erythro*-carolignan E (**5**),³ cleomiscosin A (**6**),⁴ cleomiscosin C (**7**),⁴ 9,9'-*O*-feruloyl-(–)-secoisolaricinresinol (**8**),⁵ dihydrodehydrodiconifenyl alcohol (**9**),⁶ boehmenan (**10**)³ and (–)-syringaresinol (**11**),⁷ have been isolated after series of chromatographic separations of CHCl₃ and EtOAc solubles individually. Herein, we describe the isolation, structural elucidation and cytotoxic properties of these phenylpropanoids.

2. Results and discussion

(7*S*,8*S*)-Demethylcarolignan E (**1**) was isolated as colourless amorphous powder. The HRFABMS at *m/z* 716.2464 [M]⁺ suggested the molecular formula C₃₉H₄₀O₁₃. The ¹H NMR signals at δ 3.83 (3H, s, OCH₃–3), 3.99 (1H, dd, *J* = 12.1, 4.2 Hz, H-9a), 4.16 (1H, m, H-8), 4.44 (1H, dd, *J* = 12.1, 3.0 Hz, H-9b), 5.01 (1H, d, *J* = 8.1 Hz, H-7), and 6.88–6.93 containing H-2, -5, and -6 indicated the existence of guaiacylglycerol, 4-hydroxy-3-methoxyphenyl-1,2,3-propanetriol moiety. A 3',4'-dihydroxyphenylpropanol moiety was revealed by the signals at δ 1.97 (2H, tt, *J* = 7.3, 6.3 Hz, H-8'), 2.64 (2H, t, *J* = 7.3 Hz, H-7'), 4.18 (2H, t, *J* = 6.3 Hz, H-9'), 6.61 (1H, dd, *J* = 7.9, 1.6 Hz, H-6'), 6.81 (1H, d, *J* = 1.6 Hz, H-2'), 7.00 (1H, d, *J* = 7.9 Hz, H-5'). These two units were linked together by an ether linkage

Keywords: Malvaceae; *Hibiscus taiwanensis*; Lignan; 9,9'-*O*-feruloyl-(–)-secoisolaricinresinol.

* Corresponding authors. Tel.: +886-6-2757575; fax: +886-6-2740552; e-mail addresses: wupl@mail.ncku.edu.tw; tswu@mail.ncku.edu.tw

between C-8 and C-4' as H-8 (δ 4.16) showed HMBC correlation with C-4' (δ 144.0). Two AB sets of signals at δ 6.27 (1H, d, H-8'''), 7.57 (1H, d, H-7''') and 6.29 (1H, d, H-8''), 7.60 (1H, d, H-7'') with coupling constant of 15.9 Hz for two *trans* vinylic systems together with overlapped signals in the range of 6.88–6.93 and 7.00–7.08 for H-2'', -2''', -5'', -5''', -6'', and 6''', and a six-proton singlet at δ 3.92 (OCH₃-3'', -3''') indicated that compound **1** has two feruloyl moieties. The HMBC correlations between H-9 (δ 3.99 and 4.44) and C-9'' (δ 166.9) and between H-9' (δ 4.18) and C-9' (δ 167.4) confirmed the connections of these feruloyl moieties at C-9 and C-9'. The *threo* configuration at C-7 and C-8 was inferred

by the large coupling constant of 8.1 Hz between H-7 and H-8.³ These data were very similar to those of *threo*-carolignan E (**4**) and *erythro*-carolignan E (**5**), also isolated in this study, except the presence of hydroxyl group instead of methoxyl at C-3'. Consequently, compound **1** was identified as *threo*-demethylcarolignan E.

In order to confirm this structure further, a cyclization reaction was performed in acetic acid in the presence of catalytic amount of H₂SO₄ to form benzodioxane derivative **1a** having molecular formula C₃₉H₃₈O₁₂. A water molecule was lost during the cyclization process. The HMBC correlations between H-7 (δ 4.93) and C-3'




Table 1. Comparison of the chemical shifts of C-7 and -8 for compounds **1**, **1a**, **4**, **5** in CDCl₃ and **6**, **7** in pyridine-*d*₅

Compound	Chemical shift (δ)	
	C-7	C-8
1	74.6	85.3
4	74.4	86.3
5	72.1	84.5
1a	76.6	75.7
6	77.6	79.9
7	77.9	79.9

(δ 143.4), H-8 (δ 4.25) and C-4' (δ 141.2) ascertained the formation of benzodioxane moiety. The large coupling constant of 8.0 Hz between H-7 and H-8 showed that we isolated a *threo* benzodioxane **1a**.³ The positive Cotton effect at 234 nm for **1a** indicated that it possessed the absolute configuration 8*S* according to the study of related benzodioxane system.⁸ Therefore, *threo*-**1a** have the (7*S*,8*S*) configuration and *threo*-**1** would be (7*S*,8*S*)-demethylcarolignan E. Examining the ¹³C spectral data of a series of 8-*O*-phenylpropanetriols **1**, **4** and **5** as well as benzodioxanes **1a**, **6** and **7**, it is worthy to mention that a phenyloxy group on C-8 led the chemical shifts of C-7 and C-8 around at δ 75 and 85, respectively. Once it cyclized to benzodioxane ring, C-8 was upfield-shifted and the chemical shifts were not higher than 80 (Table 1).

Hibiscuwanin A (**2**) had the molecular formula C₂₈H₂₇NO₇ as determined from HREIMS at *m/z* 489.1786. The presence of tyramine moiety in compound **2** was deduced from the ¹H NMR signals in CD₃OD at δ 2.74 (2H, t, *J* = 7.3 Hz, H-7), 3.45 (2H, t, *J* = 7.3 Hz, H-8), 6.71 (2H, d, *J* = 8.3 Hz, H-3 and 5) and 7.04 (2H, d, *J* = 8.3 Hz, H-2 and -6) and the HMBC correlation of H-7 (δ 2.74) with C-2, -6 (δ 130.7). Two AB sets of signals at δ 6.39 (d, *J* = 15.6 Hz, H-8'), 7.42 (d, *J* = 15.6 Hz, H-7') as well as 6.32 (d, *J* = 15.9 Hz, H-8''), 7.46 (d, *J* = 15.9 Hz, H-7'') for two vinylic systems with *trans* configuration and proton signals at δ 3.88 (6H, s, OCH₃-3' and -3''), 6.78 (2H, d, *J* = 8.1 Hz, H-5' and -5''), 7.02 (1H, dd, *J* = 8.1, 1.2 Hz, H-6'), 7.10 (1H, d, *J* = 1.2 Hz, H-2') as well as 7.02 (1H, dd, *J* = 8.1, 1.2 Hz, H-6''), 7.14 (1H, d, *J* = 1.2 Hz, H-2'') were consistent with the presence of two *trans* feruloyl groups in the molecule. The HMBC correlation of C-9' (δ 169.2) with H-8 (δ 3.45), H-7' (δ 7.42) and H-8' (δ 6.39) indicated an amide linkage between a feruloyl and tyramine moieties. The second feruloyl group connected to either feruloyl part or tyramine part could be determined by NOE experiment. An NOE cross peak between the signals at δ 6.78 and 6.32 assignable to H-5' and H-8'', respectively, indicated that the second feruloyl group formed an ester linkage with the OH-4' of the former feruloyl group. The structure of hibiscuwanin A (**2**), thus, concluded to be *N*-(4'-*O*-*trans*-feruloyl)-*trans*-feruloyltyramine. In deed, the hydrolysate of **2** in acidic condition yielded a compound whose ¹H NMR spectrum was identical to *N*-*trans*-feruloyltyramine.⁹

The molecular formula C₂₈H₂₇NO₇ assigned by HREIMS for compound **3** indicated it to be an isomer of **2**.

Table 2. Cytotoxicity of the compounds **1–3** and **5–10** from the stems of *H. taiwanensis* towards two human cancer lines A549 and MCF-7^a

Compound	EC ₅₀ (μ g/mL) ^b	
	A549	MCF-7
1	9.7	8.3
2	>20 (14)	>20 (36)
3	>20 (28)	>20 (40)
5	10.6	8.5
6	>20 (22)	>20 (35)
7	>20 (33)	>20 (38)
8	1.8	3.9
9	>20 (16)	>20 (48)
10	18.4	10.9

^a A549=human lung carcinoma; MCF-7=human breast carcinoma.

^b If inhibition >50% at 2.5 μ g/mL, percent observed is the value in bracket.

Accordingly, the ¹H NMR of **3** contained signals for a tyramine unit at δ 2.68 (2H, t, *J* = 7.3 Hz, H-7), 3.38 (2H, t, *J* = 7.3 Hz, H-8), 6.68 (2H, d, *J* = 8.4 Hz, H-3 and -5) and 6.98 (2H, d, *J* = 8.4 Hz, H-2 and -6); a *cis*-feruloyl group at 3.82 (3H, s, OCH₃-3'), 5.80 (1H, d, *J* = 12.6 Hz, H-8'), 6.60 (1H, d, *J* = 12.6 Hz, H-7'), 6.73 (1H, d, *J* = 8.2 Hz, H-5'), 6.92 (1H, dd, *J* = 8.2, 1.2 Hz, H-6') and 7.34 (1H, d, *J* = 1.2 Hz, H-2'); and a *trans*-feruloyl group at δ 3.88 (3H, s, OCH₃-3'), 6.31 (1H, d, *J* = 15.9 Hz, H-8''), 6.79 (1H, d, *J* = 8.0 Hz, H-5''), 7.03 (1H, dd, *J* = 8.4, 1.4 Hz, H-6''), 7.15 (1H, d, *J* = 1.4 Hz, H-2'') and 7.52 (1H, d, *J* = 15.9 Hz, H-7''). The HMBC correlation between H-8 (δ 3.38) and C-9' (δ 170.3) inferred that the *cis*-feruloyl group was connected to the nitrogen atom of tyramine through an amide bond. The NOE of OCH₃-3' (δ 3.82) with H-7'' (δ 7.52) and H-5' (δ 6.73) with H-8'' (δ 6.31) confirmed the attachment of *trans*-feruloyl group by an ester bond with OH-4 of *cis*-feruloyl unit. Hence, the structure of hibiscuwanin B (**3**) was deduced to be *N*-(4'-*O*-*trans*-feruloyl)-*cis*-feruloyltyramine. Due to the ease of *cis* and *trans* isomerization in acidic condition, it had possibility of **2** or **3** as an artefact of **3** or **2**.

The compounds **1–3**, **5–10** were subjected to cytotoxicity and anti-HIV evaluation. Among them, 9,9',-*O*-feruloyl-(–)-secoisolaricinresinol (**8**) showed strong cytotoxic activity against human lung carcinoma (A549) and breast carcinoma (MCF-7) cell lines with EC₅₀ 1.8 and 3.9 μ g/mL, respectively (Table 2) and no tested compound inhibited HIV replication in H9 lymphocyte cells.

3. Experimental section

3.1. General

Optical rotations were measured on a Jasco DIP-370 digital polarimeter. UV spectra were recorded on an Agilent 8453 spectrophotometer. IR spectra were recorded on a Nicolet Magna FT-IR spectrophotometer. NMR spectra were recorded on Bruker Avance 300 FT-NMR spectrometer; all chemical shifts were given in

ppm from tetramethylsilane as an internal standard. Mass spectra were obtained on VG 70-250S spectrometer by a direct inlet system. CD spectra were determined on a Jasco J-715 spectropolarimeter.

3.2. Plant material

The stems of *H. taiwanensis* were collected from Tainan Hsien, Taiwan, Republic of China, in February 2001. It was authenticated by Prof. C. S. Kuoh, Department of Biology, National Cheng Kung University, Tainan, Taiwan. A voucher specimen (No PLW-010001) was deposited in the Herbarium of National Cheng Kung University, Tainan, Taiwan.

3.3. Extraction and isolation

The air-dried stems of *H. taiwanensis* (20 kg) were powdered and extracted under reflux with MeOH for six times. The combined extracts were concentrated under reduced pressure to give dark brown syrup. The syrup was then suspended in H₂O and then partitioned with hexane, CHCl₃ and EtOAc, successively. The concentrated CHCl₃ layer was repeatedly chromatographed on a silica gel column by eluting with a gradient of hexane and Me₂CO (3:1 to 100% Me₂CO) to give (–)-syringaresinol (**11**) (36 mg), 9,9′-*O*-feruloyl-(–)-secoisolaricinresinol (**8**) (113 mg), boehmenan (**10**) (15 mg), *erythro*-carolignan E (**5**) (12 mg), (7*S*,8*S*)-demethylcarolignan E (**1**) (528 mg), cleomiscosin A (**6**) (10 mg), cleomiscosin C (**7**) (38 mg) and dihydrodehydrodiconiferyl alcohol (**9**) (8 mg), successively. The concentrated EtOAc layer was subjected to column chromatography on silica gel and eluted with a gradient of CHCl₃ and MeOH (9:1 to 100% MeOH) to give *threo*-carolignan E (**4**) (17 mg), hibiscuwanin A (**2**) (5 mg) and hibiscuwanin B (**3**) (8 mg).

3.3.1. (7*S*,8*S*)-Demethylcarolignan E (1**).** Colourless amorphous powder; $[\alpha]_D^{25} -4.5^\circ$ (*c* 0.12, CH₃OH); UV (CH₃OH) λ_{\max} (log ϵ) 204 (4.75), 232 (4.35), 289 (4.30), 326 (4.41) nm; IR (KBr) ν_{\max} 3450, 1695, 1646, 1540 cm^{−1}; ¹H NMR (CDCl₃) δ 1.97 (2H, tt, *J* = 7.3, 6.3 Hz, H-8′), 2.64 (2H, t, *J* = 7.3 Hz, H-7′), 3.83 (3H, s, OCH₃-3), 3.92 (6H, s, OCH₃-3′ and -3′′), 3.99 (1H, dd, *J* = 12.1, 4.2 Hz, H-9a), 4.16 (1H, m, H-8), 4.18 (2H, t, *J* = 6.3 Hz, H-9′), 4.44 (1H, dd, *J* = 12.1, 3.0 Hz, H-9b), 5.01 (1H, d, *J* = 8.1 Hz, H-7), 6.27 (1H, d, *J* = 15.9 Hz, H-8′′), 6.29 (1H, d, *J* = 15.9 Hz, H-8′′), 6.61 (1H, dd, *J* = 7.9, 1.6 Hz, H-6′), 6.81 (1H, d, *J* = 1.6 Hz, H-2′), 6.88–6.93 (5H, m, H-2, -5, -5′, -5′′, -6), 7.00 (1H, d, *J* = 7.9 Hz, H-5′), 7.00–7.08 (4H, m, H-2′, -2′′, -6′, -6′′), 7.57 (1H, d, *J* = 15.9 Hz, H-7′′), 7.60 (1H, d, *J* = 15.9 Hz, H-7′′); ¹³C NMR (CDCl₃) δ 30.2 (C-8′), 31.6 (C-7′), 56.0 (3×OCH₃), 62.8 (C-9), 63.7 (C-9′), 74.6 (C-7), 85.3 (C-8), 108.9 (C-2), 109.4 (C-2′′), 109.5 (C-2′), 114.4 (C-5′′), 114.6 (C-5′′), 114.7 (C-5 and -8′′), 115.4 (C-8′′), 115.9 (C-2′), 119.8 (C-6′), 120.1 (C-6), 120.3 (C-5′), 123.1 (C-6′′), 123.2 (C-6′′), 126.7 (C-1′′), 126.9 (C-1′), 131.0 (C-1), 138.1 (C-1′), 144.0 (C-4′), 144.9 (C-7′′),

145.9 (C-7′′), 146.1 (C-3′), 146.8 (C-3′′ and -3′′′), 146.9 (C-3), 147.9 (C-4), 148.2 (C-4′′), 148.6 (C-4′), 166.9 (C-9′′), 167.4 (C-9′); FABMS *m/z* (rel int.) 716 ($[M]^+$, 2), 699 ($[M-H_2O+H]^+$, 4), 177 (100); HRFABMS *m/z* 716.2464 $[M]^+$ (calcd for C₃₉H₄₀O₁₃, 716.2469), 699.2437 $[M-H_2O+H]^+$ (calcd for C₃₉H₃₉O₁₂, 699.2436).

3.3.2. Cyclization of (7*S*,8*S*)-demethylcarolignan E (1**) in HOAc.**¹⁰ (7*S*,8*S*)-Demethylcarolignan E (**1**) (100 mg, 0.14 mmol) and 5% H₂SO₄ (1.5 mL) were added to 10 mL of HOAc. The resulting mixture was heated at 60 °C with stirring for 20 min. After cooling, water was added to the solution, neutralized with NaHCO₃ and extracted with EtOAc. The EtOAc extract was washed with water, dried over anhydrous MgSO₄ and evaporated under high vacuum. The crude product was purified by column chromatography on silica gel using CHCl₃–MeOH (30:1) eluent to yield pure (7*S*,8*S*)-benzodioxane **1a** as colourless amorphous powder (82 mg, 84% yield): $[\alpha]_D^{25} +14.4^\circ$ (*c* 0.41, CH₃OH); UV (CH₃OH) λ_{\max} (log ϵ) 232 (4.60), 289 (4.48), 326 (4.62) nm; IR (KBr) ν_{\max} 3419, 1701, 1633, 1593, 1514 cm^{−1}; ¹H NMR (CDCl₃) δ 1.98 (2H, tt, *J* = 7.5, 6.3 Hz, H-8′), 2.67 (2H, t, *J* = 7.5 Hz, H-7′), 3.86 (3H, s, OCH₃-3), 3.91 (6H, s, OCH₃-3′ and -3′′), 4.12 (1H, dd, *J* = 12.3, 4.2 Hz, H-9a), 4.21 (2H, t, *J* = 6.3 Hz, H-9′), 4.25 (1H, m, H-8), 4.35 (1H, dd, *J* = 12.3, 2.6 Hz, H-9b), 4.93 (1H, d, *J* = 8.0 Hz, H-7), 5.84 (1H, br s, OH-4), 6.05 (2H, br s, OH-4′ and -4′′), 6.29 (2H, d, *J* = 15.9 Hz, H-8′ and -8′′), 6.75 (1H, dd, *J* = 8.1, 1.5 Hz, H-6′), 6.84 (1H, d, *J* = 1.5 Hz, H-2′), 6.87 (1H, s, H-2), 6.92 (5H, m, H-5, -5′, -5′′, -6), 7.02 (2H, s, H-2′ and -2′′), 7.07 (2H, d, *J* = 8.3 Hz, H-6′ and -6′′), 7.57 and 7.59 (1H each, d, *J* = 15.9 Hz, H-7′ and -7′′); ¹³C NMR (CDCl₃) δ 30.2 (C-8′), 31.4 (C-7′), 55.9 (3×OCH₃), 63.0 (C-9), 63.6 (C-9′), 75.7 (C-8), 76.6 (C-7), 109.4 (C-2, -2′ and -2′′), 114.4 and 115.4 (C-8′ and -8′′), 114.7 (C-5, -5′ and -5′′), 116.9 (C-2′ and -5′), 120.7 (C-6), 121.6 (C-6′), 123.0 and 123.2 (C-6′ and -6′′), 126.6 and 126.9 (C-1′ and -1′′), 127.7 (C-1), 134.7 (C-1′), 141.2 (C-4′), 143.4 (C-3′), 144.8 and 145.6 (C-7′ and -7′′), 146.7 (C-4), 146.8 (C-3′ and -3′′), 146.9 (C-3), 147.9 and 148.2 (C-4′ and -4′′), 166.7 (C-9′′), 167.3 (C-9′); FABMS *m/z* (rel int.) 698 ($[M]^+$, 11), 177 (100); HRFABMS *m/z* 698.2362 $[M]^+$ (calcd for C₃₉H₃₈O₁₂, 698.2363). CD (CH₃OH, 1.7 × 10^{−4} M) $[\theta]_{234}^{25} +357$, $[\theta]_{267}^{25} +936$, $[\theta]_{281}^{25} -999$, $[\theta]_{284}^{25} +1664$, $[\theta]_{288}^{25} -1066$.

3.3.3. Hibiscuwanin A (2**).** Pale yellow amorphous powder; UV (CH₃OH) λ_{\max} (log ϵ) 290 (4.23), 318 (4.30) nm; IR (KBr) ν_{\max} 3305, 1698, 1634, 1575, 1523 cm^{−1}; ¹H NMR (CD₃OD) δ 2.74 (2H, t, *J* = 7.3 Hz, H-7), 3.45 (2H, t, *J* = 7.3 Hz, H-8), 3.88 (6H, s, OCH₃-3′ and -3′′), 6.32 (1H, d, *J* = 15.9 Hz, H-8′), 6.39 (1H, d, *J* = 15.6 Hz, H-8′), 6.71 (2H, d, *J* = 8.3 Hz, H-3 and 5), 6.78 (2H, d, *J* = 8.1 Hz, H-5′ and 5′′), 7.02 (2H, dd, *J* = 8.1, 1.2 Hz, H-6′ and -6′′), 7.04 (2H, d, *J* = 8.3 Hz, H-2 and -6), 7.10 (1H, d, *J* = 1.2 Hz, H-2′), 7.14 (1H, d, *J* = 1.2 Hz, H-2′′), 7.42 (1H, d, *J* = 15.6 Hz, H-7′), 7.46 (1H, d, *J* = 15.9 Hz, H-7′′); ¹³C NMR (CD₃OD) δ 35.8 (C-7), 42.5 (C-8), 56.4 (OCH₃-3′ and -3′′), 111.5 (C-2′ and -2′′), 116.3 (C-3 and -5),

116.5 (C-5' and -5''), 118.7 (C-8'), 119.3 (C-8''), 123.2 (C-6'), 123.4 (C-6''), 128.3 (C-1'), 128.5 (C-1''), 130.7 (C-2 and 6), 131.3 (C-1), 142.0 (C-7'), 144.4 (C-7''), 149.3 (C-3' and -3''), 149.8 (C-4' and 4''), 156.9 (C-4), 169.2 (C-9'), 173.3 (C-9''); EIMS m/z (rel int.) 489 (M^+ , 5), 369 (9), 192 (96), 177 (85), 145 (34), 120 (40), 107 (100), 77 (75), 51 (40); HR-EIMS m/z 489.1786 [M] $^+$ (calcd for $C_{28}H_{27}NO_7$, 489.1788).

3.3.4. Hibiscuwanin B (3). Pale yellow amorphous powder; UV (CH_3OH) λ_{max} (log ϵ) 288 (4.19), 315 (4.22) nm; IR (KBr) ν_{max} 3345, 1694, 1633, 1593, 1515 cm^{-1} ; 1H NMR (CD_3OD) δ 2.68 (2H, t , $J = 7.3$ Hz, H-7), 3.38 (2H, t , $J = 7.3$ Hz, H-8), 3.82 (3H, s , OCH_3 -3'), 3.88 (3H, s , OCH_3 -3''), 5.80 (1H, d , $J = 12.6$ Hz, H-8'), 6.31 (1H, d , $J = 15.9$ Hz, H-8''), 6.60 (1H, d , $J = 12.6$ Hz, H-7'), 6.68 (2H, d , $J = 8.4$ Hz, H-3 and -5), 6.73 (1H, d , $J = 8.2$ Hz, H-5'), 6.79 (1H, d , $J = 8.0$ Hz, H-5''), 6.92 (1H, dd , $J = 8.2$, 1.2 Hz, H-6'), 6.98 (2H, d , $J = 8.4$ Hz, H-2 and -6), 7.03 (1H, dd , $J = 8.0$, 1.4 Hz, H-6''), 7.15 (1H, d , $J = 1.4$ Hz, H-2''), 7.34 (1H, d , $J = 1.2$ Hz, H-2'), 7.52 (1H, d , $J = 15.9$ Hz, H-7''); ^{13}C NMR (CD_3OD) δ 35.6 (C-7), 42.4 (C-8), 56.4 (OCH_3 -3' and -3''), 111.6 (C-2''), 113.9 (C-2'), 115.8 (C-5''), 116.2 (C-3 and -5), 116.4 (C-5'), 117.7 (C-8''), 121.6 (C-8'), 123.7 (C-6''), 124.8 (C-6'), 128.2 (C-1''), 128.5 (C-1'), 130.7 (C-2 and -6), 131.2 (C-1), 138.4 (C-7'), 145.6 (C-7''), 148.5 (C-4'), 149.3 (C-3' and -4''), 150.1 (C-3''), 156.9 (C-4), 170.3 (C-9'), 172.2 (C-9''); EIMS m/z (rel int.) 489 (M^+ , 12), 369 (36), 352 (25), 192 (32), 177 (53), 120 (41), 107 (100), 77 (69), 65 (23), 51 (29); HR-EIMS m/z 489.1790 [M] $^+$ (calcd for $C_{28}H_{27}NO_7$, 489.1788).

3.3.5. Cytotoxicity and anti-HIV assay. The cytotoxicity and anti-HIV assays were carried out according to the procedure described in the literature.^{11,12}

Acknowledgements

The authors would like to thank the National Science Council of the Republic of China for the financial support (NSC 90-2323-B-006-003). We also thank Prof. Kuo-Hsiung Lee, Natural Products Laboratory, School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, USA, for the cytotoxicity and anti-HIV assays.

References and notes

- Liao, J. C. 2nd ed.; *Flora of Taiwan*; Editorial Committee of the Flora of Taiwan: Taipei, Taiwan, 1993; Vol. 3. p 743.
- The preliminary result of the cytotoxicity assay was performed by the Division of Biotechnology and Pharmaceutical Research in National Health Research Institutes.
- Seca, A. M. L.; Silva, A. M. S.; Silvestre, A. J. D.; Cavaleiro, J. A. S.; Domingues, F. M. J.; Pascolal-Neto, C. *Phytochemistry* **2001**, 56, 759.
- Ray, A. B.; Chattopadhyay, S. K.; Kumar, S. *Tetrahedron* **1985**, 41, 209.
- Fuchino, H.; Satoh, T.; Tanaka, N. *Chem. Pharm. Bull.* **1995**, 43, 1937.
- Hanawa, F.; Shiro, M.; Hayashi, Y. *Phytochemistry* **1997**, 45, 589.
- Buske, A.; Schmidt, J.; Porzei, A.; Adam, G. *Phytochemistry* **1997**, 46, 1385.
- Da Silva, M. S.; Barbosa-Filho, J. M.; Yoshida, M.; Gottlibe, O. R. *Phytochemistry* **1989**, 28, 3477.
- Wu, P. L.; Su, G. C.; Wu, T. S. *J. Nat. Prod.* **2003**, 66, 996.
- Tanaka, H.; Kato, I.; Ito, K. *Chem. Pharm. Bull.* **1985**, 33, 3218.
- Hayashi, K.; Nakanishi, Y.; Bastow, K. F.; Cragg, G.; Nozaki, H.; Lee, K. H. *J. Nat. Prod.* **2003**, 66, 125.
- Hirata, K.; Ito, C.; Furukawa, H.; Itoigawa, M.; Cosen-tino, L. M.; Lee, K. H. *Bioorg. Med. Chem.* **1999**, 9, 119.